Bristol-Myers Squibb Company PFD CONV 2
BMYMP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$8,933 | $8,040 | $6,345 | $7,014 |
| Dep. & Amort. | $9,600 | $9,760 | $10,276 | $10,686 |
| Deferred Tax | -$2,089 | -$3,288 | -$2,738 | -$1,393 |
| Stock-Based Comp. | $507 | $518 | $457 | $583 |
| Change in WC | $810 | -$1,914 | -$2,229 | -$1,261 |
| Other Non-Cash | $15,295 | $744 | $955 | $578 |
| Operating Cash Flow | $15,190 | $13,860 | $13,066 | $16,207 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,248 | -$1,209 | -$1,118 | -$973 |
| Net Acquisitions | -$20,722 | -$260 | -$2,981 | -$862 |
| Inv. Purchases | -$769 | -$1,774 | -$3,592 | -$5,478 |
| Inv. Sales/Matur. | $1,387 | $948 | $6,629 | $6,775 |
| Other Inv. Act. | $0 | $0 | $0 | $0 |
| Investing Cash Flow | -$21,352 | -$2,295 | -$1,062 | -$538 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $10,096 | $456 | -$5,311 | -$6,182 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | -$5,155 | -$8,001 | -$6,287 |
| Dividends Paid | -$4,863 | -$4,744 | -$4,634 | -$4,396 |
| Other Fin. Act. | -$106 | $27 | $984 | $641 |
| Financing Cash Flow | $5,127 | -$9,416 | -$16,962 | -$16,224 |
| Forex Effect | -$137 | $45 | -$33 | -$102 |
| Net Chg. in Cash | -$1,172 | $2,194 | -$4,991 | -$657 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $11,519 | $9,325 | $14,316 | $14,973 |
| End Cash | $10,347 | $11,519 | $9,325 | $14,316 |
| Free Cash Flow | $13,942 | $12,651 | $11,948 | $15,234 |